Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

Countries covered: Global The global market for healthcare-acquired infection treatments were $16 billion in year 2010. This market is estimated to be around $19 billion in the year 2011 and is forecasted to cross $30 billion by 2016 at a CAGR of 9.5% for five year period. Markets for infection control devices and products were $8.3 billion in the year 2010 and are expected to reach $10.3 billion by 2011. This market is forecasted to cross $18.3 billion by 2016 at a CAGR of 12%. The market for pharmaceutical treatments is expected to be around $4.5 billion. This market is expected to increase at a 5.8% compound annual growth rate (CAGR) to reach $6 billion by 2016.

Additional Information

INTRODUCTION

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of the selected areas of the global healthcare-acquired infection (HAI) market. HAI is sometimes used to mean hospital-acquired infections, but for purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers, and dialysis centers. Another term for healthcare-acquired infections is nosocomial infections.

The focus of this report is on devices, pharmaceuticals, and therapies currently used or under development for treatment of viral, bacterial, or fungal infections.

The global market for HAI products is estimated at between $10 billion and $15 billion in 2010, depending on the products included in the study, with high single-digit growth through 2016. Although the U.S. holds between 45% and 50% of the market, the fastest-growing regions for HAI treatments are the Asia-Pacific, which includes China, and Brazil.

STUDY GOALS AND OBJECTIVES

Healthcare-acquired infections are viral, bacterial, or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters, and intravenous lines.

The Centers for Disease Control (CDC) estimates that 2 million HAIs occur annually in the U.S. This leads to 100,000 deaths and costs an additional $36 billion to $45 billion in direct medical costs annually.

This report is designed to investigate the global HAI market by treatment area and by treatment type, with supporting tables and figures to illustrate projected growth. The report will include the U.S., Europe, Japan, and other countries such as China.

This report offers forecasts of the markets for devices, pharmaceuticals, and therapies by treatment segment and treatment type from 2011 through 2016, including supporting analyses for projections.

This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. It provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.

This is an invaluable tool for business planners; acquisition specialists; licensing strategists; product managers; market research analysts; investing consultants; and others interested in the HAI market, its products, its participants, and its future.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was obtained from various primary and secondary research sources, including industry analysts, annual reports, Securities and Exchange Commission (SEC) reports, the World Health Organization (WHO), the National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS), government agencies outside the U.S, and journal articles. Secondary sources include literature searches, product literature, and press releases.

When precise information was unavailable, a consensus is made using reasonable assumptions and estimates based on historical data.

More Global Infectious Diseases Reports

2012 World Infectious Disease Testing Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the infectious disease testing market environment, structure, size and growth. Includes estimates of the number of laboratories ...

2012 Global Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies by Venture Planning Group
The infectious disease testing market is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers ...

Global Infectious Disease Treatment Market 2011-2014 by Infiniti Research Limited
TechNavio’s analysts forecast the Global Infectious Disease Treatment market to grow at a CAGR of 8.1 percent over the period 2011–2014. One of the key ...

World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections) by Kalorama Information
This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment: Antifungals (Allylamines, Azoles, ...

Future Infectious Disease Testing Market: Growth Opportunities, Business Strategies, Market Entry Barriers and Risks by Venture Planning Group
The report identifies the major opportunities for infectious disease testing instrumentation, reagent kits/test panels, consumables, as well as IT and auxiliary products; proposes design criteria ...

See all reports like this >>